about Photosynthetic Harvest Inc.

Ira Pastor ipastor at phiroots.com
Mon Aug 3 09:15:36 EST 1998


Based upon the group's plant biology interests, I thought I
should introduce our company's portfolio of biotechnologies.

Please contact me if you have any questions.

Thank you.

Ira S. Pastor=20
Director

phone - 609-835-1600
fax-609-835-8510
Photosynthetic Harvest Inc.
Hill International Bldg, Suite 3
1 Levitt Pkwy  =20
Willingboro, NJ 08046

ABOUT PHOTOSYNTHETIC HARVEST, INC.
       =20
STRATEGIC INTENT
Photosynthetic Harvest Inc. (PHI), in collaboration  with the laboratory
of Ilya Raskin at Rutgers University, is developing technologies which
enable the discovery and manufacturing of biologically active compounds
from plants for uses such as pharmaceuticals, nutraceuticals, fine and
industrial chemicals, natural biopesticides, food additives, cosmetic
and health care products, pigments, flavorings and fragrances.

MARKET OPPORTUNITY AND FOCUS
Over the last 25 years, approximately 25% of all prescriptions dispensed
in the United States contained active agents derived from higher plants.
Although the technologies used to discover these pharmaceuticals are
highly sophisticated, most methods used to acquire new compounds from
higher plants belong to the age of hunter-gatherers. This mismatch
between the beginning of the drug development pipeline and what follows
creates a major opportunity that PHI has exploited.

PHI will initially focus its proprietary technology on pharmaceutical,
agricultural, and  nutraceutical markets.  PHI seeks to enable partners
to discover and/or manufacture bioactive products through corporate
partnerships, licensing of its RhizEx=99  library, and/or research
agreements.

PROPRIETARY TECHNOLOGIES
PHI, in collaboration with Rutgers University, has developed the
RHIZOSECRETION=99
platform technology, which harnesses the biosynthetic capacity of a
green plant on a scale previously not attained.  It exploits the
round-the-clock ability of a living plant to produce a greater diversity
of organic molecules than attained with conventional synthetic chemistry
or biomass extraction.

Specifically, the RHIZOSECRETION technology takes advantage of the
ability of a green plant to continuously secrete (exude) large
quantities of organic compounds and proteins from its roots. Different
plant species constantly synthesize and exude unique, highly bioactive
organic compounds whose chemical composition or function has never been
determined.=20

Compounds exuded from roots of hydroponically-grown plants are not mere
leakage products, but are evolutionarily perfected signaling and defense
molecules synthesized in response to various environmental signals.
Root-exuded compounds, naturally produced or bioengineered, can be
effectively collected in a specially constructed hydroponic system
developed by PHI. This RHIZOSECRETION process, conceptually similar to
natural rubber or maple syrup production, allows continuous harvesting
of valuable natural products and recombinant proteins from living
plants. The yield of a single plant product harvested in the
RHIZOSECRETION system over time may exceed the weight of the plant
producing it.  In addition, the purification of individual compounds or
proteins produced via RHIZOSECRETION is a relatively simple task
compared to tissue extraction methods. RHIZOSECRETION, thus, offers a
tremendous manufacturing potential that has never been tapped.

In another breakthrough, PHI has developed chemical and physical
treatments (elicitors), which mimic various stresses encountered by a
plant and stimulate roots to produce and exude arrays of new compounds.=20
In addition to stimulating the appearance of new compounds in the root
extracts and exudates, proprietary elicitation protocols developed by
PHI cause a reproducible order of magnitude increase in the yield of
many target molecules. Elicitation of hydroponically grown roots allows
PHI to access a new and unexplored dimension of chemical diversity
normally hidden in silent parts of the plant genome.=20

TECHNOLOGY AND PRODUCT PORTFOLIO=20
PHI's family of proprietary new technologies are protected by patent
applications filed by Rutgers University and exclusively licensed to
PHI.  They include:

=B7 RhizEx=99 bio-combinatorial libraries:  a continuously expanding libr=
ary
of novel, bioactive phytochemicals synthesized and exuded by elicited
and non-elicited roots of hundreds of plant species. RhizEx libraries
are composed of exudates and complimentary root extracts (elicidates).
The chemical composition of each elicidate and exudate is unique,
depending on the elicitor and plant species used for its production, and
is highly reproducible. RhizEx=99 libraries are designed for use in lead
discovery screens and are supported by an extensive proprietary
database. Currently, the RhizEx  library of exudates and elicidates
contains approximately 2,000 samples. These samples are relatively
simple mixtures, making isolation of active molecules readily
achievable. In addition, RhizEx samples are devoid of pigments and
tannins, known to interfere in activity screens.=20

=B7 RHIZOSECRETION-based phytomanufacturing of natural products:  a
proprietary process which allows reproducible, cost effective and
environmentally safe re-supply and large-scale manufacturing of any lead
compounds discovered in RhizEx libraries.=20

=B7 RHIZOSECRETION-based phytomanufacturing of recombinant proteins:=20
RHIZOSECRETION offers a low-cost, large-scale recombinant protein
production system with simplified downstream processing. In addition,
RHIZOSECRETION-based protein production may provide desired
post-translational modifications lacking in some heterologous expression
systems. Manufacturing of recombinant proteins and peptides, one of the
most scientifically advanced and technically sophisticated applications
of RHIZOSECRETION, has been successfully tested by PHI using human and
microbial proteins.=20

COMPETITIVE ADVANTAGES
PHI's key competitive advantages include:

=B7 Phytochemicals produced and secreted by plant roots, as well as those
produced by the process of elicitation, constitute novel sources of
bioactive lead compounds.=20

=B7 PHI's scientifically controlled, reproducible process of generating
compounds ensures the reliable and economical re-supply of any active
lead compound discovered.=20

=B7 The RHIZOSECRETION technology enables cost-effective, large-scale
commercial manufacturing of target phytochemicals and recombinant
proteins.
=20
CURRENT   STATUS
 The Company was incorporated in 1996 and signed agreements with Rutgers
University for an exclusive technology license and an R&D contract,
effective October, 1997.  In addition to funding from private investors,
PHI, in collaboration with Rutgers University, was awarded funding under
the Technology Transfer Program of the New Jersey Commission on Science
and Technology to accelerate the development of its proprietary
technologies.  PHI opened its office in Willingboro, New Jersey and its
scale-up greenhouse facility in Columbus, New Jersey in January, 1998.=20
The PHI-Rutgers team currently employees 16 full-time scientists and
administrators.



More information about the Plantbio mailing list